These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

948 related articles for article (PubMed ID: 16307470)

  • 1. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
    Srinivas NR
    Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous chiral analyses of multiple analytes: case studies, implications and method development considerations.
    Srinivas NR
    Biomed Chromatogr; 2004 Dec; 18(10):759-84. PubMed ID: 15584016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing need for bioanalysis during drug development.
    Srinivas NR
    Biomed Chromatogr; 2008 Mar; 22(3):235-43. PubMed ID: 17939165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
    Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Separation and sample pre-treatment in bioanalysis using monolithic phases: A review.
    Saunders KC; Ghanem A; Boon Hon W; Hilder EF; Haddad PR
    Anal Chim Acta; 2009 Oct; 652(1-2):22-31. PubMed ID: 19786168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative high-throughput analysis of drugs in biological matrices by mass spectrometry.
    Hopfgartner G; Bourgogne E
    Mass Spectrom Rev; 2003; 22(3):195-214. PubMed ID: 12838545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-content micronucleus assay in genotoxicity profiling: initial-stage development and some applications in the investigative/lead-finding studies in drug discovery.
    Mondal MS; Gabriels J; McGinnis C; Magnifico M; Marsilje TH; Urban L; Collis A; Bojanic D; Biller SA; Frieauff W; Martus HJ; Suter W; Bentley P
    Toxicol Sci; 2010 Nov; 118(1):71-85. PubMed ID: 20631060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Method for rapid metabolite profiling of drug candidates in fresh hepatocytes using liquid chromatography coupled with a hybrid quadrupole linear ion trap.
    Gao H; Materne OL; Howe DL; Brummel CL
    Rapid Commun Mass Spectrom; 2007; 21(22):3683-93. PubMed ID: 17937450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism.
    Baillie TA
    Chem Res Toxicol; 2008 Jan; 21(1):129-37. PubMed ID: 18052111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging applications of kinetic biomarkers in preclinical and clinical drug development.
    Turner SM; Hellerstein MK
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):115-26. PubMed ID: 15679179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitigating permeability-mediated risks in drug discovery.
    Wang J; Skolnik S
    Expert Opin Drug Metab Toxicol; 2010 Feb; 6(2):171-87. PubMed ID: 20064074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring drug-protein interaction.
    Yang XX; Hu ZP; Chan SY; Zhou SF
    Clin Chim Acta; 2006 Mar; 365(1-2):9-29. PubMed ID: 16199025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug disposition of chiral and achiral drug substrates metabolized by cytochrome P450 2D6 isozyme: case studies, analytical perspectives and developmental implications.
    Srinivas NR
    Biomed Chromatogr; 2006; 20(6-7):466-91. PubMed ID: 16779774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations.
    Zhu M; Zhang D; Zhang H; Shyu WC
    Biopharm Drug Dispos; 2009 May; 30(4):163-84. PubMed ID: 19544287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A holistic strategy for characterizing the safety of metabolites through drug discovery and development.
    Walker D; Brady J; Dalvie D; Davis J; Dowty M; Duncan JN; Nedderman A; Obach RS; Wright P
    Chem Res Toxicol; 2009 Oct; 22(10):1653-62. PubMed ID: 19715349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent development in software and automation tools for high-throughput discovery bioanalysis.
    Shou WZ; Zhang J
    Bioanalysis; 2012 May; 4(9):1097-109. PubMed ID: 22612689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in high-throughput quantitative bioanalysis by LC-MS/MS.
    Xu RN; Fan L; Rieser MJ; El-Shourbagy TA
    J Pharm Biomed Anal; 2007 Jun; 44(2):342-55. PubMed ID: 17360141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered disposition of drugs in acute renal failure rat models: drug development strategies and perspectives.
    Srinivas NR
    Arzneimittelforschung; 2010; 60(12):731-48. PubMed ID: 21265465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.